Israel-based Teva said it had already launched its dry powder inhaler, DuoResp Spiromax, in Britain on Monday – before the court ruling – but that the judgment dispelled any risks associated with the launch.
The inhaler has already been launched in Germany, Denmark and Portugal and the British court ruling will facilitate its sale in other European markets, the company said on Wednesday.
A spokesman added the inhaler would be a “significant” product for the company, but did not give any numbers.
Symbicort is AstraZeneca’s third-biggest selling drug, with worldwide sales of just under $1.9 billion in the first half of 2014.
While Teva’s product uses the same active ingredients as Symbicort, formoterol and budesonide, the inhalers differ in design. Economic Times